Olga Millán1, Klemens Budde2, Claudia Sommerer3, Irene Aliart1, Olesja Rissling2, Beatriz Bardaji4, Maaren Matz2, Martin Zeier3, Irene Silva4, Lluis Guirado4, Mercè Brunet1. 1. Pharmacology and Toxicology Laboratory, CDB, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Spain. 2. Medizinische Klinik mit Schwerpunkt Nephrologie, Charité Universitätsmedizin Berlin, Berlin, Germany. 3. Department of Nephrology, University of Heidelberg, University Hospital of Heidelberg and Mannheim, Heidelberg, Germany. 4. Renal Transplant Unit, Nephrology Department, Fundació Puigvert, Barcelona, Spain.
Abstract
AIMS: MicroRNAs (miRNAs) may be useful biomarkers of rejection and allograft outcome in kidney transplantation. Elevated urinary CXCL10 levels have been associated with acute rejection (AR) and may predict allograft failure. We examined the correlation of miRNA, CXCL10 levels and immunosuppressive drug exposure with AR and graft function in kidney transplant recipients. METHODS: Eighty de novo kidney transplant recipients were recruited from four European centres. All patients received tacrolimus, mycophenolate mofetil, and methylprednisolone. Urinary pellet expression of miR-142-3p, miR-210-3p and miR-155-5p was assessed by quantitative real-time polymerase chain reaction and urinary CXCL10 levels by enzyme-linked immunosorbent assay at the 1st week and the 1st , 2nd , 3rd and 6th months post-transplantation. RESULTS: Eight patients experienced AR. Before and during AR, patients showed a significant increase of urinary miR-142-3p, miR-155-5p and CXCL10 levels and a decrease of miR-210-3p levels. Receiver operating characteristic curve analysis showed that miR-155-5p (area under the curve = 0.875; P = 0.046) and CXCL10 (area under the curve = 0.865; P = 0.029) had excellent capacity to discriminate between rejectors and nonrejectors. The optimal cut-off values for the prognosis of AR were 0.51, with 85% sensitivity and 86% specificity for miR-155-5p and 84.73 pg ml-1 , with 84% sensitivity and 80% specificity for CXCL10. miR-155-5p and CXCL10 levels correlated with glomerular filtration rate. Levels of both biomarkers normalized after recovery of graft function. CONCLUSIONS: The regular early post-transplantation monitoring of urinary miR-155-5p and CXCL10 can help in the prognosis of AR and graft dysfunction. Large prospective randomized multicentre trials are warranted to refine our cut-off values and validate the clinical usefulness of these biomarkers.
AIMS: MicroRNAs (miRNAs) may be useful biomarkers of rejection and allograft outcome in kidney transplantation. Elevated urinary CXCL10 levels have been associated with acute rejection (AR) and may predict allograft failure. We examined the correlation of miRNA, CXCL10 levels and immunosuppressive drug exposure with AR and graft function in kidney transplant recipients. METHODS: Eighty de novo kidney transplant recipients were recruited from four European centres. All patients received tacrolimus, mycophenolate mofetil, and methylprednisolone. Urinary pellet expression of miR-142-3p, miR-210-3p and miR-155-5p was assessed by quantitative real-time polymerase chain reaction and urinary CXCL10 levels by enzyme-linked immunosorbent assay at the 1st week and the 1st , 2nd , 3rd and 6th months post-transplantation. RESULTS: Eight patients experienced AR. Before and during AR, patients showed a significant increase of urinary miR-142-3p, miR-155-5p and CXCL10 levels and a decrease of miR-210-3p levels. Receiver operating characteristic curve analysis showed that miR-155-5p (area under the curve = 0.875; P = 0.046) and CXCL10 (area under the curve = 0.865; P = 0.029) had excellent capacity to discriminate between rejectors and nonrejectors. The optimal cut-off values for the prognosis of AR were 0.51, with 85% sensitivity and 86% specificity for miR-155-5p and 84.73 pg ml-1 , with 84% sensitivity and 80% specificity for CXCL10. miR-155-5p and CXCL10 levels correlated with glomerular filtration rate. Levels of both biomarkers normalized after recovery of graft function. CONCLUSIONS: The regular early post-transplantation monitoring of urinary miR-155-5p and CXCL10 can help in the prognosis of AR and graft dysfunction. Large prospective randomized multicentre trials are warranted to refine our cut-off values and validate the clinical usefulness of these biomarkers.
Authors: Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath Journal: Br J Pharmacol Date: 2015-07 Impact factor: 8.739
Authors: M Matz; J Beyer; D Wunsch; M-F Mashreghi; M Seiler; J Pratschke; N Babel; H-D Volk; P Reinke; K Kotsch Journal: Kidney Int Date: 2006-05 Impact factor: 10.612
Authors: Joshua M Rosenblum; Naohiko Shimoda; Austin D Schenk; Howard Zhang; Danielle D Kish; Karen Keslar; Joshua M Farber; Robert L Fairchild Journal: J Immunol Date: 2010-03-01 Impact factor: 5.422
Authors: To-Ha Thai; Dinis Pedro Calado; Stefano Casola; K Mark Ansel; Changchun Xiao; Yingzi Xue; Andrew Murphy; David Frendewey; David Valenzuela; Jeffery L Kutok; Marc Schmidt-Supprian; Nikolaus Rajewsky; George Yancopoulos; Anjana Rao; Klaus Rajewsky Journal: Science Date: 2007-04-27 Impact factor: 47.728
Authors: W W Hancock; B Lu; W Gao; V Csizmadia; K Faia; J A King; S T Smiley; M Ling; N P Gerard; C Gerard Journal: J Exp Med Date: 2000-11-20 Impact factor: 14.307
Authors: Kristien J Ledeganck; Els M Gielis; Daniel Abramowicz; Peter Stenvinkel; Paul G Shiels; Amaryllis H Van Craenenbroeck Journal: Clin J Am Soc Nephrol Date: 2019-01-02 Impact factor: 8.237
Authors: Olga Millán; Pablo Ruiz; Lara Orts; Paula Ferré; Gonzalo Crespo; Miguel Santana; Virginia Fortuna; Luís Quintairos; Miguel Navasa; Mercè Brunet Journal: Front Immunol Date: 2019-04-24 Impact factor: 7.561
Authors: Els M Gielis; Jacqueline D H Anholts; Els van Beelen; Geert W Haasnoot; Hans W De Fijter; Ingeborg Bajema; Sebastiaan Heidt; Mathijs van de Vrie; Luuk B Hilbrands; Marko J K Mallat; Kristien J Ledeganck; Frans H J Claas; Michael Eikmans Journal: Transplant Direct Date: 2021-06-10